SCHEMBL6524183

SCHEMBL6524183

Cc1c(-c2ccccc2)nc2ccc(-c3cccc(F)c3CO)cn12

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
DHODH Q02127 1/20 0.44
LRRK2 Q5S007 2/20 0.42
ABL1 P00519 1/20 0.42
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
SLC2A1 P11166 6/20 0.39
KDM4E B2RXH2 2/20 0.39
ALDH1A1 P00352 1/20 0.39
HTT P42858 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
MAPT P10636 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
CYP11B1 P15538 2/20 0.38
CYP11B2 P19099 2/20 0.38
TGFBR1 P36897 3/20 0.38
NR1H4 Q96RI1 2/20 0.38
SLC2A2 P11168 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3431442 0.91 NR4A2 (0.47) LRRK2ABL1SLC2A1ALDH1A1MAPT
SCHEMBL6523033 0.89 CYP11B1 (0.44) DHODHLRRK2ABL1NPC1RAB9A
SCHEMBL6521811 0.88 TRPA1 (0.42) LRRK2ABL1SLC2A1MAPTCYP11B1
SCHEMBL6519571 0.88 NR4A2 (0.50) DHODHNPC1RAB9ASLC2A1KDM4E
SCHEMBL6524569 0.85 DHODH (0.43) DHODHLRRK2ABL1CYP11B1CYP11B2
SCHEMBL3430234 0.84 NR1H4 (0.41) LRRK2ABL1SLC2A1TGFBR1NR1H4
SCHEMBL6521387 0.79 NR4A2 (0.51) NPC1RAB9ASLC2A1MAPTCYP11B1
SCHEMBL6520541 0.79 NR4A2 (0.61) SLC2A1ALDH1A1MAPTCYP1A2CYP2C9
SCHEMBL6523662 0.76 CYP2C9 (0.48) NPC1RAB9ASLC2A1KDM4EMAPT
SCHEMBL6527443 0.76 NR4A2 (0.47) NPC1RAB9ASLC2A1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2262769-B1 POLYSUBSTITUTED 2-ARYL-6-PHENYL-IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2014-11-05 EP claimed
EP-2262769-B1 POLYSUBSTITUTED 2-ARYL-6-PHENYL-IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2014-11-05 EP disclosed
US-20110065745-A1 POLYSUBSTITUTED 2-ARYL-6-PHENYLIMIDAZO[1,2-A]PYRIDINE DERIVATIVES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065745-A1 POLYSUBSTITUTED 2-ARYL-6-PHENYLIMIDAZO[1,2-A]PYRIDINE DERIVATIVES, AND PREPARATION AND THERAPEUTIC USE THEREOF JAK2, ABL1, REN DHODH 2143/4885LRRK2 1212/4885ABL1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.